The N-end rule pathway is a conserved proteolytic system that governs protein turnover by recognising specific destabilising residues at the N-terminus of substrates – so‐called N‐degrons. This ...

This article is based on a poster originally authored by Mat Calder, Ben Durham, Amy Prosser, Miguel Coelho, Aimee Blair, Jack Cobb, Marta Falcicchio, Ruben Alvarez Fernandez, Emma Ford, Alberto ...

In the world of protein degradation, sometimes a spanner in the works isn’t an inconvenience but the desired result. Paris-based Enodia Therapeutics has launched out of France’s Pasteur Institute and ...

Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programsPresentations reinforce potential of degraders ...

Targeted protein degradation (TPD) approaches including PROTAC and molecular glue have revolutionized drug discovery. However, in part due to complication of the ubiquitination and related ...

Therapeutics that leverage protein degradation as their primary mechanism of action appear to be a validated new therapeutic modality. The current clinical molecules are focused on degrading ...

Edited by: Thomas W. Durso and Karen Young Kreeger M. Hochstrasser, "Ubiquitin, proteasomes, and the regulation of intracellular protein degradation," Current Opinion in Cell Biology, 7:215-23, 1995. ...

Intracellular protein trafficking and secretion of proteins into the extracellular environment are sequential and tightly regulated processes in eukaryotic cells. Conventionally, proteins that are ...

Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural protein disposal systems to eliminate disease-causing proteins. Innovators are making rapid and ...

Three posters accepted at AACR 2026 highlighting SK Life Science Labs' targeted protein degradation pipeline -- Programs featured: selective p300 and PRMT5 degraders -- p300 degrader data demonstrate: ...